NCI SEER Program. Cancer stat facts: kidney and renal pelvis cancer. 2023.

Speed JM, Trinh QD, Choueiri TK, Sun M. Recurrence in localized renal cell carcinoma: a systematic review of contemporary data. Curr Urol Rep. 2017;18:15.

Article  PubMed  Google Scholar 

Terrone C, Cracco C, Porpiglia F, et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol. 2006;49:324–31.

Article  PubMed  Google Scholar 

Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163:1090–5 quiz 1295.

Article  CAS  PubMed  Google Scholar 

Wang LL, Saidian A, Pan E, et al. Adjuvant therapy in renal cell carcinoma: are we ready for prime time? Kidney Cancer. 2023;7:1–11.

Article  Google Scholar 

Mir MC, Derweesh I, Porpiglia F, et al. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol. 2017;71:606–17.

Article  PubMed  Google Scholar 

Dhanji S, Wang L, Liu F, et al. Recent advances in the management of localized and locally advanced renal cell carcinoma: a narrative review. Res Rep Urol. 2023;15:99–108.

PubMed  PubMed Central  Google Scholar 

Yim K, Aron M, Rha KH, et al. Outcomes of robot-assisted partial nephrectomy for clinical T3a renal masses: a multicenter analysis. Eur Urol Focus. 2021;7:1107–14.

Article  PubMed  Google Scholar 

Andrade HS, Zargar H, Akca O, et al. Is robotic partial nephrectomy safe for T3a renal cell carcinoma? Experience of a high-volume center. J Endourol. 2017;31:153–7.

Article  PubMed  Google Scholar 

Campbell SC, Clark PE, Chang SS, et al. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J Urol. 2021;206:199–208.

Article  PubMed  Google Scholar 

Pierorazio PM, Johnson MH, Patel HD et al. AHRQ comparative effectiveness reviews. In Management of renal masses and localized renal cancer. Rockville (MD): Agency for Healthcare Research and Quality (US) 2016.

Pierorazio PM, Johnson MH, Patel HD, et al. Management of renal masses and localized renal cancer: systematic review and meta-analysis. J Urol. 2016;196:989–99.

Article  PubMed  PubMed Central  Google Scholar 

Campbell SC, Uzzo RG, Karam JA, et al. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part II. J Urol. 2021;206:209–18.

Article  PubMed  Google Scholar 

McKay RR. The promise of adjuvant immunotherapy in renal-cell carcinoma. N Engl J Med. 2021;385:756–8.

Article  CAS  PubMed  Google Scholar 

Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246–54.

Article  CAS  PubMed  Google Scholar 

Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eisen T, Frangou E, Oza B, et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial. J Clin Oncol. 2020;38:4064–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Russo P, Haas N, et al. Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 PROTECT trial. Eur Urol. 2021;79:334–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol. 2018;29:2371–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683–94. This landmark trial stablished the role of adjuvant pembrolizumab in RCC.

Article  CAS  PubMed  Google Scholar 

Choueiri T, Tomczak P, Park SH, et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: results from 30-month follow-up of KEYNOTE-564. J Clin Oncol. 2023;40:abstr 290. This reference showed the efficacy of adjuvant pembrolizumab in RCC after extended follow-up.

Article  Google Scholar 

Borregales LD, Adibi M, Thomas AZ, et al. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2016;8:130–41.

Article  CAS  PubMed  Google Scholar 

Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:eaax0 182.

Article  CAS  Google Scholar 

Gorin MA, Patel HD, Rowe SP, et al. Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma. Eur Urol Oncol. 2022;5:113–7.

Article  PubMed  Google Scholar 

Carlo MI, Attalla K, Mazaheri Y, et al. Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy. Eur Urol. 2022;81:570–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaur J, Patil G, Geynisman DM, Ghatalia P. Role of perioperative immunotherapy in localized renal cell carcinoma. Ther Adv Med Oncol. 2023;15:17588359231181496.

Article  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289–96.

Article  CAS  PubMed  Google Scholar 

Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–9. This reference proposed the IMDC prognostic criteria in RCC.

Article  CAS  PubMed  Google Scholar 

Kroeger N, Xie W, Lee JL, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer. 2013;119:2999–3006.

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90 (Landmark CheckMate 214 trial).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–27. This landmark trial established the role of pembrolizumab/axitinib in first-line RCC.

Article  CAS  PubMed  Google Scholar 

Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829–41. Landmark CheckMate 9ER trial.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384:1289–300. Landmark CLEAR tria l.

Article  CAS  PubMed  Google Scholar 

Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128:2085–97. This reference showed the extended follow-up of CheckMate 214 and continued to show the efficacy of ipilimumab/nivolumab in the first-line setting.

Article  CAS  PubMed  Google Scholar 

Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. J Clin Oncol. 2023;41:LBA4501–LBA4501. This reference showed the extended follow-up of KEYNOTE-426 and continued to show the efficacy of pembrolizumab/axitinib in the first-line setting.

Article  Google Scholar 

Burotto M, Powles T, Escudier B, et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. J Clin Oncol. 2023;41:603–603. This reference showed the extended follow-up of CheckMate 9ER and continued to show the efficacy of nivolumab/cabozantinib in the first-line setting.

Motzer RJ, Porta C, Eto M, et al. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2023;41:4502–4502. This reference showed the extended follow-up of CLEAR and continued to show the efficacy of pembrolizumab/lenvatinib in the first-line setting.

Article  Google Scholar 

National Comprehensive Cancer Network. Kidney Cancer 2023.

Choueiri TK, Powles T, Albiges L, et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med. 2023;388:1767–78. Triplet study which investigated ipilimumab/nivolumab/cabozantinib in first-line RCC.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rini BI, Signoretti S, Choueiri TK, et al. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. J Immunother Cancer. 2022;10:e005445.

Article  PubMed  PubMed Central  Google Scholar 

Choueiri T, Plimack ER, Powles T, et al. Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC). J Clin Oncol. 2022;40:abstr TPS99. Ongoing trial of the triplet regimens in first-line RCC.